Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KINSHIP-OLE long-term danicamtiv extension in symptomatic genetic and familial dilated cardiomyopathy
2026-526139-20-00Phase 3Authorised
- Sponsor
- Kardigan
- Start
- Oct 2026
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, open-label, single-arm trial of danicamtiv in familial dilated cardiomyopathy (FDCM), sponsored by Kardigan. Primary endpoints: Long-term safety and tolerability and Clinical safety assessments. Planned start Oct 2026; status: authorised.
02
Drugs
danicamtiv
03
Conditions
familial dilated cardiomyopathy (FDCM)
Beyond the preview
Go deeper on 2026-526139-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526139-20-00.